Navigation Links
News from Molecular Medicine
Date:5/20/2010

Cystic Fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

Manhasset, NY (Vocus) May 20, 2010 -- In the latest issue of Molecular Medicine, cystic fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

In other studies in the latest issue of Molecular Medicine, a team of Brazilian scientists tested the activity of a novel angiotensin converting enzyme (ACE) in thrombus formation in animals that were either hypertensive or not. They reported that the pharmacological activation of the ACE2 receptor with the experimental ligand reduced platelet attachment to vessels and thrombus formation. These results suggest that this could be a potential lead compound for the treatment of thrombogenic diseases.

Other findings in the journal include a pivotal discovery of immune regulation of cancer cells, an endogenous factor that works in wound healing, a gene therapy study on Fabry Disease, a study on the immunological properties at work in Celiac disease, and a new molecular fingerprint of lung injury.

Molecular Medicine is published by The Feinstein Institute for Molecular Research. The peer-reviewed journal strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. The journal, a bimonthly publication, serves as a forum through which scientists and researchers can communicate recent discoveries to a multi-disciplinary, international audience interested in understanding and curing disease.

To listen to the latest podcast on these studies visit www.molmed.org/podcast.html.

###

Read the full story at http://www.prweb.com/releases/Molecular-Medicine/cystic-fibrosis/prweb4017864.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular marker could help spot pancreatic cancer early
2. Molecular discovery points to new therapies for brain tumors
3. USC researchers discover new molecular subtype of brain cancer
4. The Association for Molecular Pathology celebrates ruling in DNA patent case
5. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
6. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
7. Molecular pathways linked to sex, age affect outcomes in lung cancer
8. Ground Breaking Molecular Diagnostics Business Appoints New CEO
9. Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantation
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. News from the Latest Issue of Molecular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
News from Molecular Medicine
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... , ... February 05, 2016 , ... After years as ... Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of ... He successfully completed his first three-year term as chief and began a second three-year ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to feel ... be safer than regular municipal or well water. The recent experience with lead contaminated ... could go a long way toward increasing public acceptance of recycled waste water as ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. ... announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. ... range of oral health care, including general dentistry, cosmetic treatments, periodontics, implant ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
(Date:2/4/2016)... 2016 Global Immunology Market to 2022 ... long-term market growth Summary Immune-mediated inflammatory ... disorders that affect 5–7% of western populations. Although ... symptoms and key patient demographics, they are pathophysiologically ... and an inappropriate immune response. Generally, disease-modifying anti-rheumatic ...
(Date:2/4/2016)... 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... devices to treat life-threatening diseases, today announced results ... December 31, 2015. --> ... forth in our last quarterly call, we strategically ... long-term objective to establish the Aethlon Hemopurifier® as ...
Breaking Medicine Technology: